0001127602-24-009302.txt : 20240311
0001127602-24-009302.hdr.sgml : 20240311
20240311090511
ACCESSION NUMBER: 0001127602-24-009302
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240307
FILED AS OF DATE: 20240311
DATE AS OF CHANGE: 20240311
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Klinger Shannon Thyme
CENTRAL INDEX KEY: 0001866132
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38753
FILM NUMBER: 24736727
MAIL ADDRESS:
STREET 1: 200 TECHNOLOGY SQUARE
STREET 2: SUITE 300
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Moderna, Inc.
CENTRAL INDEX KEY: 0001682852
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 813467528
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 6177146500
MAIL ADDRESS:
STREET 1: 200 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: Moderna Therapeutics, Inc.
DATE OF NAME CHANGE: 20160822
4
1
form4.xml
PRIMARY DOCUMENT
X0508
4
2024-03-07
0001682852
Moderna, Inc.
MRNA
0001866132
Klinger Shannon Thyme
200 TECHNOLOGY SQUARE
SUITE 300
CAMBRIDGE
MA
02139
1
Chief Legal Officer
1
Common Stock
2024-03-07
4
M
0
1138
A
9811
D
Common Stock
2024-03-08
4
S
0
544
99.0509
D
9267
D
Restricted Stock Units
2024-03-07
4
M
0
1138
0
D
Common Stock
1138
5694
D
Restricted stock units convert into common stock on a one-for-one basis.
Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive
plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
25% of the shares subject to this restricted stock unit award vested on June 7, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
/s/ James Dillon, as Attorny-in-Fact
2024-03-11